poisar

Stocks · News reference

Fortrea to Participate in Jefferies Global Healthcare Conference

Fortrea announced that its executive leadership team will participate in the upcoming Jefferies Global Healthcare Conference in London.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

FTRE
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Collaboration entre Fortrea et Omico pour faire progresser le développement de médicaments oncologiques basés sur des biomarqueurs

    Fortrea, a leading global contract research organization, has announced a collaboration with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven oncology drug development. The partnership combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve clinical trial planning, site selection, and patient recruitment for targeted cancer therapies in Australia.

    FTRE
  2. Na

    Fortrea 與 Omico 攜手合作，推動生物標記主導的腫瘤藥物開發

    Fortrea, a leading Contract Research Organization (CRO), has partnered with Omico, Australia's precision oncology screening platform, to accelerate biomarker-driven cancer clinical trials in Australia. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve trial planning, site selection, and patient recruitment, leveraging Omico's database of over 23,000 consented patients and referrals from 1,600+ clinicians across Australia.

    FTRE
  3. Na

    Fortrea und Omico kooperieren zur Förderung der biomarkergestützten Entwicklung von Krebsmedikamenten

    Fortrea, a leading global clinical research organization, has partnered with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven cancer drug development. The collaboration combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve study planning, patient recruitment, and access to biomarker-based clinical trials in Australia, leveraging Omico's database of over 23,000 patients and referrals from 1,600+ Australian physicians.

    FTRE